{{medical}}
{{Drugbox
| verifiedrevid = 477172111
| IUPAC_name = 4-amino-''N''-(2-diethylaminoethyl) benzamide
| image = Procainamide.svg

<!--Clinical data-->
| tradename = Pronestyl，Procan，Procanbid
| Drugs.com = {{drugs.com|monograph|procainamide-hydrochloride}}
| pregnancy_US = C
| legal_UK = POM
| routes_of_administration = [[静脉注射|静脉注射]]，[[肌肉注射|肌肉注射]]，口服

<!--Pharmacokinetic data-->
| bioavailability = 85%（口服）
| protein_bound = 15至20%
| metabolism = [[肝脏|肝脏]]（由[[CYP2D6|CYP2D6]]调节）
| elimination_half-life = 约2.5至4.5小时
| excretion = [[肾脏|肾脏]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-06-9
| ATC_prefix = C01
| ATC_suffix = BA02
| ATC_supplemental =  
| PubChem = 4913
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01035
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4744
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L39WTC366D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08421
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8428
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 640

<!--Chemical data-->
| C=13 | H=21 | N=3 | O=1 
| molecular_weight = 235.325 g/mol
| smiles = O=C(c1ccc(N)cc1)NCCN(CC)CC
| InChI = 1/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
| InChIKey = REQCZEXYDRLIBE-UHFFFAOYAM
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = REQCZEXYDRLIBE-UHFFFAOYSA-N
}}

'''普鲁卡因胺'''（[[国际非专利药品名称|INN]]：'''Procainamide'''，{{IPAc-en|icon|p|r|oʊ|ˈ|k|eɪ|n|əm|aɪ|d}}）是一种Ia类[[抗心律失常药|抗心律失常药]]，用于治疗[[心律不整|心律不整]]。

==历史==
普鲁卡因胺在1951年由[[百时美施贵宝|百时美施贵宝]]研制成功。<ref name="pmid18610401">{{cite journal |author=Hollman A |title=Procaine and procainamide |journal=Br Heart J |volume=67 |issue=2 |pages=143 |pmid=18610401 |pmc=1024743 |doi= 10.1136/hrt.67.2.143|url=|date=February 1992}}</ref> 它在1950年6月2日被美国食品药品监督管理局批准以Pronestyl的商品名上市。<ref name=dafda>{{cite web  |title=Drugs at FDA: FDA Approved Drug Products |url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm |publisher=U.S. Food and Drug Administration (FDA) |location=USA |accessdate=2012-08-13}}</ref>

==作用机理==
普鲁卡因胺是一种[[钠通道阻滞剂|钠通道阻滞剂]]，能够阻断[[钠通道|钠通道]]，抑制[[钠|钠]]离子（Na<sup>+</sup>）内流（还可能抑制[[钾|钾]]离子内流），从而延长[[心脏|心脏]][[动作电位|动作电位]]。这使得传导变慢，最终动作电位的上升速率减小，导致[[QRS复合波|QRS复合波]]变宽，心律不齐得到缓解。<ref name="Zamponi Sui Codding French 1993 pp. 2324–2334">{{cite journal | last=Zamponi | first=G.W. | last2=Sui | first2=X. | last3=Codding | first3=P.W. | last4=French | first4=R.J. | title=Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation | journal=Biophysical Journal | publisher=Elsevier BV | volume=65 | issue=6 | year=1993 | issn=0006-3495 | doi=10.1016/s0006-3495(93)81291-8 | pages=2324–2334}}</ref>

==用途==
普鲁卡因胺能用于治疗所有的心律不齐，包括了室上性心律失常和室性心律失常——例如[[心房颤动|心房颤动]]（但这种情况下不是[[一线药物|最佳选择]]）。<ref name="Fenster Comess Marsh Katzenberg 1983 pp. 501–504">{{cite journal | last=Fenster | first=Paul E | last2=Comess | first2=Keith A | last3=Marsh | first3=Randall | last4=Katzenberg | first4=Charles | last5=Hager | first5=W.David | title=Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion | journal=American Heart Journal | publisher=Elsevier BV | volume=106 | issue=3 | year=1983 | issn=0002-8703 | doi=10.1016/0002-8703(83)90692-0 | pages=501–504}}</ref> 它还被用于治疗[[预激综合征|预激综合征]]，并能够延长[[旁道|旁道]]的[[不应期|不应期]]。<ref>{{cite journal|title=Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome|pages=15–22|issn=0009-7322|journal=Circulation|volume=55|issue=1|date=1977-1|url=https://www.ncbi.nlm.nih.gov/pubmed/830205|accessdate=2019-02-13|author=T. D. Sellers, R. W. Campbell, T. M. Bashore, J. J. Gallagher|pmid=830205}}</ref>

==给药==
普鲁卡因胺能够口服、静脉注射和肌肉注射。当静脉注射时最开始应采用[[负荷剂量|负荷剂量]]，但必须注意不要引起[[低血压|低血压]]。负荷剂量为100mg，在五分钟内注射完；最大剂量则是17mg/kg。当心律不齐被抑制、低血压症状出现、QRS复合波变宽50%或以上，以及最大剂量达到的时候则停止用药。

==代谢==
普鲁卡因胺的主要代谢产物是N-乙酰基普鲁卡因胺（NAPA），该物质抗心律不齐能力与原药几乎相同。<ref>{{cite journal | pmid = 902457 | year = 1977 | last1 = Dutcher | first1 = JS | last2 = Strong | first2 = JM | last3 = Lucas | first3 = SV | last4 = Lee | first4 = WK | last5 = Atkinson Jr | first5 = AJ | title = Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology | volume = 22 | issue = 4 | pages = 447–57 | journal = Clinical pharmacology and therapeutics}}</ref> NAPA的[[生物半衰期|生物半衰期]]大约是普鲁卡因胺的两倍，因此它在缓慢注射药物的时候有可能达到一个较高的胞内浓度，引起低血压。<ref>{{cite journal | pmid = 4834444 | year = 1974 | last1 = Drayer | first1 = DE | last2 = Reidenberg | first2 = MM | last3 = Sevy | first3 = RW | title = N-acetylprocainamide: An active metabolite of procainamide | volume = 146 | issue = 2 | pages = 358–63 | journal = Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine}}</ref>

==副作用==
[[副作用|副作用]]包括[[皮疹|皮疹]]、[[肌痛|肌痛]]、[[超敏反应|超敏反应]]（[[发热|发热]]与[[粒细胞缺乏症|粒细胞缺乏症]]）、[[药源性红斑狼疮|药源性红斑狼疮]]（尤其对于慢乙酰化者），<ref name="pmid9851277">{{cite journal |author=Kameda H, Mimori T, Kaburaki J, ''et al.'' |title=Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome |journal=Br. J. Rheumatol. |volume=37 |issue=11 |pages=1236–9 |pmid=9851277 |doi= 10.1093/rheumatology/37.11.1236|url=http://rheumatology.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9851277|date=November 1998}}</ref> 及药物本身引起的心律不齐。其中药源性红斑狼疮相对于其他药物来说较为常见，原因是普鲁卡因胺的治疗使人体产生自身细胞结构的[[抗体|抗体]]。

==参考资料==
{{reflist|2}}

==外部链接==
*[http://www.pubpk.org/index.php?title=Procainamide PubPK - Procainamide]

{{Antiarrhythmic agents}}
{{Calcium channel blockers}}

[[Category:抗心律失常药|Category:抗心律失常药]]
[[Category:苯酰胺类|Category:苯酰胺类]]
[[Category:苯胺|Category:苯胺]]